Decrease in the apparent diffusion coefficient in peritumoral edema for the assessment of recurrent glioblastoma...

Area of Science:

• Neuro-oncology
• Radiology
• Medical imaging

Background:

• Recurrent glioblastoma presents significant treatment challenges.
• Bevacizumab is a targeted therapy used in oncology.
• Peritumoral edema is a common complication of brain tumors.

Purpose of the Study:

• To evaluate the anti-edema effect of bevacizumab in recurrent glioblastoma.
• To correlate changes in apparent diffusion coefficient (ADC) with regional cerebral blood flow (rCBV).
• To assess the impact of bevacizumab on tumor edema using MRI.

Main Methods:

• Nine patients with recurrent glioblastoma received bevacizumab treatment.
• Serial MRI scans were performed every 2 months.
• Apparent diffusion coefficient (ADC), regional cerebral blood flow (rCBV), and contrast-enhancing tumor volume were measured.

Main Results:

• Bevacizumab treatment led to a significant decrease in ADC and rCBV values within 2 months.
• A marked reduction in contrast-enhancing tumor volume was observed.
• At 6 months, 5 patients showed recurrence of enhancement, while 4 maintained initial improvements.

Conclusions:

• Bevacizumab demonstrates a potent and prolonged anti-edema effect in recurrent glioblastoma.
• Decreased ADC and rCBV values indicate bevacizumab's efficacy in managing peritumoral edema.
• The anti-edema effect persisted for at least 6 months, despite tumor progression in some cases.